Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-05, Stock:ABBV, The news for the past five days is as follows:
2018-08-28: NEWS1: AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know.NEWS2: AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know.NEWS3: AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know.NEWS4: AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma.NEWS5: AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma.NEWS6: AbbVie&apos;s Imbruvica Combo Gets FDA Nod for Rare Lymphoma.NEWS7: Biotech Stocks Take Aim At New Highs In August 2018.NEWS8: AbbVie to Present at the Morgan Stanley 16th Annual Global Healthcare Conference.
2018-08-29: NEWS1: CLASS ACTION UPDATE for MD and ABBV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders.NEWS2: SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) and Lead Plaintiff Deadline – September 24, 2018.NEWS3: Europe ready to cash in on cheap copies of AbbVie biotech drug.NEWS4: FOCUS-Europe ready to cash in on cheap copies of AbbVie biotech drug.
2018-08-30: NEWS1: 3 High-Yield Healthcare Dividend Stocks Still Worth Buying.NEWS2: 3 High-Yield Healthcare Dividend Stocks Still Worth Buying.
2018-08-31: NEWS1: Do the Risks in Marijuana Stocks Outweigh the Rewards?.NEWS2: Do the Risks in Marijuana Stocks Outweigh the Rewards?.NEWS3: Do the Risks in Marijuana Stocks Outweigh the Rewards?.NEWS4: Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus.NEWS5: Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus.NEWS6: Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK&apos;s HIV Drug in Focus.NEWS7: 4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline.
2018-09-04: NEWS1: Vertex Inks Reimbursement Agreement for Orkambi in Australia.NEWS2: Vertex Inks Reimbursement Agreement for Orkambi in Australia.NEWS3: These Monthly Dividend Stocks Are Set to Surge (and pay up to 6.8%).NEWS4: These Monthly Dividend Stocks Are Set to Surge (and pay up to 6.8%).NEWS5: Is Now a Good Time to Buy Gilead Sciences?.NEWS6: Is Now a Good Time to Buy Gilead Sciences?.NEWS7: AbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of Dermatology and Venereology (EADV) Congress.NEWS8: Is Now a Good Time to Buy Gilead Sciences?.

Answer: Rise